RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Immuno-Biological Laboratories Co Stock

Immuno-Biological Laboratories Co ROE 2024

Immuno-Biological Laboratories Co ROE

0.15

Ticker

4570.T

ISIN

JP3921300004

In 2024, Immuno-Biological Laboratories Co's return on equity (ROE) was 0.15, a -178.02% increase from the -0.19 ROE in the previous year.

Immuno-Biological Laboratories Co Aktienanalyse

What does Immuno-Biological Laboratories Co do?

Immuno-Biological Laboratories Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Immuno-Biological Laboratories Co's Return on Equity (ROE)

Immuno-Biological Laboratories Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Immuno-Biological Laboratories Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Immuno-Biological Laboratories Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Immuno-Biological Laboratories Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Immuno-Biological Laboratories Co stock

What is the ROE (Return on Equity) of Immuno-Biological Laboratories Co this year?

The ROE of Immuno-Biological Laboratories Co this year is 0.15 undefined.

How has the Return on Equity (ROE) of Immuno-Biological Laboratories Co developed compared to the previous year?

The ROE of Immuno-Biological Laboratories Co has increased by -178.02% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Immuno-Biological Laboratories Co?

A high ROE indicates that Immuno-Biological Laboratories Co generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Immuno-Biological Laboratories Co?

A low ROE can indicate that Immuno-Biological Laboratories Co is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Immuno-Biological Laboratories Co affect the company?

A change in ROE (Return on Equity) of Immuno-Biological Laboratories Co can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Immuno-Biological Laboratories Co?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Immuno-Biological Laboratories Co?

Some factors that can influence Immuno-Biological Laboratories Co's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Immuno-Biological Laboratories Co pay?

Over the past 12 months, Immuno-Biological Laboratories Co paid a dividend of 5 JPY . This corresponds to a dividend yield of about 1.13 %. For the coming 12 months, Immuno-Biological Laboratories Co is expected to pay a dividend of 0 JPY.

What is the dividend yield of Immuno-Biological Laboratories Co?

The current dividend yield of Immuno-Biological Laboratories Co is 1.13 %.

When does Immuno-Biological Laboratories Co pay dividends?

Immuno-Biological Laboratories Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immuno-Biological Laboratories Co?

Immuno-Biological Laboratories Co paid dividends every year for the past 0 years.

What is the dividend of Immuno-Biological Laboratories Co?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immuno-Biological Laboratories Co located?

Immuno-Biological Laboratories Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immuno-Biological Laboratories Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immuno-Biological Laboratories Co from 6/28/2013 amounting to 50 JPY, you needed to have the stock in your portfolio before the ex-date on 3/27/2013.

When did Immuno-Biological Laboratories Co pay the last dividend?

The last dividend was paid out on 6/28/2013.

What was the dividend of Immuno-Biological Laboratories Co in the year 2023?

In the year 2023, Immuno-Biological Laboratories Co distributed 0 JPY as dividends.

In which currency does Immuno-Biological Laboratories Co pay out the dividend?

The dividends of Immuno-Biological Laboratories Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immuno-Biological Laboratories Co

Our stock analysis for Immuno-Biological Laboratories Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immuno-Biological Laboratories Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.